|
Originally published In Press as doi:10.1074/jbc.M105518200 on August 24, 2001
J. Biol. Chem., Vol. 276, Issue 43, 39959-39967, October 26, 2001
The Muscle-specific Protein Phosphatase
PP1G/RGL(GM) Is Essential for Activation of
Glycogen Synthase by Exercise*
William G.
Aschenbach §,
Yoichi
Suzuki¶ ,
Kristine
Breeden¶,
Clara
Prats¶,
Michael F.
Hirshman ,
Scott
D.
Dufresne ,
Kei
Sakamoto ,
Pier Giuseppe
Vilardo¶,
Marcella
Steele¶,
Jong-Hwa
Kim¶,
Shao-liang
Jing**,
Laurie J.
Goodyear , and
Anna A.
DePaoli-Roach¶
From the Research Division, Joslin Diabetes Center
and Harvard Medical School, Boston, Massachusetts 02215 and the
¶ Department of Biochemistry and Molecular Biology and the
** Krannert Institute of Cardiology, Indiana University
School of Medicine, Indianapolis, Indiana 46202
Received for publication, June 14, 2001, and in revised form, August 7, 2001
 |
ABSTRACT |
In skeletal muscle both insulin and
contractile activity are physiological stimuli for glycogen synthesis,
which is thought to result in part from the dephosphorylation and
activation of glycogen synthase (GS).
PP1G/RGL(GM) is a glycogen/sarcoplasmic reticulum-associated type 1 phosphatase that was originally postulated to mediate insulin control of glycogen metabolism. However, we recently
showed (Suzuki, Y., Lanner, C., Kim, J.-H., Vilardo, P. G., Zhang,
H., Jie Yang, J., Cooper, L. D., Steele, M., Kennedy, A., Bock,
C., Scrimgeour, A., Lawrence, J. C. Jr., L., and
DePaoli-Roach, A. A. (2001) Mol. Cell. Biol. 21, 2683-2694) that insulin activates GS in muscle of
RGL(GM) knockout (KO) mice similarly to the
wild type (WT). To determine whether PP1G is involved in glycogen
metabolism during muscle contractions, RGL KO and
overexpressors (OE) were subjected to two models of contraction,
in vivo treadmill running and in situ
electrical stimulation. Both procedures resulted in a 2-fold increase
in the GS /+ glucose-6-P activity ratio in WT mice, but this response
was completely absent in the KO mice. The KO mice, which also have a
reduced GS activity associated with significantly reduced basal
glycogen levels, exhibited impaired maximal exercise capacity, but
contraction-induced activation of glucose transport was unaffected. The
RGL OE mice are characterized by enhanced GS activity ratio
and an ~3-4-fold increase in glycogen content in skeletal muscle.
These animals were able to tolerate exercise normally. Stimulation of
GS and glucose uptake following muscle contraction was not
significantly different as compared with WT littermates. These results
indicate that although PP1G/RGL is not necessary for
activation of GS by insulin, it is essential for regulation of glycogen
metabolism under basal conditions and in response to contractile
activity, and may explain the reduced muscle glycogen content in the
RGL KO mice, despite the normal insulin activation of
GS.
 |
INTRODUCTION |
Insulin and contractile activity are major regulators of glycogen
metabolism in skeletal muscle. Insulin stimulates glycogen synthesis,
and postprandially, ~80% of ingested glucose is taken up by skeletal
muscle and converted to glycogen (1, 2). Under these conditions,
insulin activates glycogen synthase
(GS),1 as well as glucose
transport, via translocation of the GLUT4 transporter (3, 4). Glycogen
is a major fuel for the contractile activity of skeletal muscle. During
contraction, glycogen is utilized as a source of energy, and it has
been demonstrated that, perhaps paradoxically, glycogen resynthesis
occurs while glycogen is being broken down (5, 6). Presumably, this
represents a mechanism for the rapid replenishment of glycogen stores
when exercise ceases (7, 8). Contraction also promotes glucose uptake
but most likely via a mechanism distinct from that triggered by insulin (9-12). Insulin-stimulated glucose uptake is blocked by the
phosphatidylinositol 3-kinase (PI-3K) inhibitor, wortmannin. In
contrast, the increased glucose uptake induced by exercise is
wortmannin-insensitive, and the AMP-activated protein kinase (AMPK)
(13, 14) has been postulated to play an important role. The period
following exercise is characterized by increased glucose uptake and net
glycogen synthesis in skeletal muscle, a scenario similar to insulin
stimulation of muscle. Despite the fact that the mechanism of GS
activation in response to insulin has been extensively studied, the
molecular details of both insulin and contraction-induced activation
remain mostly unknown.
Glycogen metabolism is controlled largely by the coordinated action of
the two enzymes GS and glycogen phosphorylase (Ph). Both enzymes are
controlled by covalent phosphorylation and by allosteric effectors
(15-17). GS undergoes a complex multisite phosphorylation at nine
sites by several protein kinases (17), most notably
cAMP-dependent protein kinase, casein kinase I, casein kinase II, GSK-3, and AMPK (18) which generally lead to inactivation. Important regulatory phosphorylation sites are distributed between the
NH2 (sites 2 and 2a) and the COOH termini (sites 3a and 3b) of the GS molecule (19-21). Full activity can be restored to
phosphorylated enzyme by the presence of the allosteric activator
glucose-6-P (G-6P). Ph is activated by phosphorylation of a single site
by phosphorylase kinase (22). The less active, dephosphorylated form
(Ph b) acquires full activity in the presence of the
allosteric effector AMP. Dephosphorylation of all three of these key
regulatory proteins, GS, Ph, and phosphorylase kinase, is believed to
be catalyzed primarily by glycogen-associated phosphatases (PP1Gs) (23).
The three forms of PP1G present in skeletal muscle consist of a
catalytic subunit, PP1c, in association with a glycogen-targeting subunit, PTG, R6, or RGL (also called GM
(24-28)). RGL is striated muscle specific, whereas the
other two subunits are more ubiquitously distributed. PTG may interact
with glycogen-metabolizing enzymes (29) and has been implicated in
insulin control of glycogen metabolism (25, 30). Adenovirus-mediated
overexpression of PTG in cultured human muscle cells results in
glycogen accumulation and activation of GS (31). However, the
mechanism(s) of regulation of PTG and R6-associated phosphatases are
completely unknown.
The muscle-specific phosphatase PP1G/RGL, composed of PP1c
associated with RGL (GM), dephosphorylates the
regulatory sites on GS as well as on Ph and phosphorylase kinase (23,
27). Phosphatase activity was thought to be regulated hormonally by phosphorylation of site 1 (Ser48) and site 2 (Ser67) on the RGL subunit (32, 33).
Phosphorylation of site 1 by the insulin-stimulated protein kinase
p90Rsk would enhance association of PP1c to RGL
and therefore activity toward GS and phosphorylase kinase (32).
Conversely, phosphorylation of site 2 would cause dissociation of PP1c
and greatly reduced activity (33). However, work from several
laboratories (34-37) has demonstrated that insulin control of glycogen
metabolism does not involve the mitogen-activated protein (MAP) kinase
pathway. These studies did not exclude the possibility that insulin
could activate PP1G/RGL via other pathways. Our recent
observations (38) showed that RGL null mice have
significant reductions in basal GS /+ G-6P activity ratio and total
activity and muscle glycogen content. However, RGL KO and
wild type mice exhibited a similar 2-fold activation of GS in skeletal
muscle in response to insulin stimulation. These studies clearly
demonstrate that PP1G/RGL is not essential for the hormonal
control. Instead a novel GS-specific insulin-stimulated type 1 phosphatase was detected (38), indicating that a distinct phosphatase
form may be involved. A large body of evidence suggests that insulin
activation of GS proceeds via the PI-3K/Akt pathway that leads to
phosphorylation and inhibition of GSK-3 (39-41). However, GSK-3 alone
is not sufficient to account for GS dephosphorylation and activation by
insulin (3, 20, 21). The mTOR, mammalian target for the
immunosuppressant drug rapamycin, pathway is also activated by insulin.
Rapamycin has been shown to block insulin-mediated activation of GS in
muscle and 3T3-L1 adipocytes (35, 39) without affecting insulin-induced inactivation of GSK-3 (42), opening the possibility that mTOR could
control GS phosphorylation via a phosphatase. Therefore, insulin may
promote glycogen synthesis both via inhibition of GSK-3 and
stimulation of a type 1 phosphatase.
Even though PP1G/RGL is not required for insulin-stimulated
glycogen synthesis in skeletal muscle, it may be a component of the
response to contractile activity. GS has been shown to be regulated
differentially in skeletal muscle by insulin and contractions during
in vitro and in vivo studies (43-45), with
contractions and exercise resulting in a prolonged, substantially
greater activation compared with maximal insulin treatment. This
suggests that contractions may utilize a separate signaling pathway
from insulin to activate GS in response to contractions. Changes in GS
activity in human muscle biopsy samples obtained during isometric
contractions are associated with changes in protein phosphatase
activity (46), but the identity of this enzyme has not been determined.
The purpose of the present study was to examine whether the low
skeletal muscle glycogen content in RGL KO mice would lead
to impaired exercise capacity and to investigate the role of
PP1G/RGL in glycogen metabolism during muscle contraction.
Our approach was to use two different models of exercise: in
vivo treadmill running and in situ muscle contraction
in mice that either overexpress or are deficient in the RGL
subunit. We demonstrate that GS activation is abolished in
RGL KO mice during both in vivo and in
situ models of exercise. This finding provides compelling evidence
that PP1G/RGL is essential for activation of GS during
exercise and may provide a mechanism to explain the reduced muscle
glycogen content despite the normal insulin control of GS in the KO mice.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Aspergillus niger amyloglucosidase,
yeast hexokinase, and yeast glucose 6-phosphate (G-6P) dehydrogenase
were purchased from Sigma. Restriction enzymes were from New England
Biolabs (Beverly, MA). Taq polymerase was purchased from
Promega. Radioactively labeled nucleotides,
-D-[U-14C]glucose-1-phosphate,
UDP[U-14C]glucose, and [3H]2-deoxyglucose
were purchased from PerkinElmer Life Sciences. Okadaic acid was from
Roche Molecular Biochemicals. Oligonucleotides were synthesized by Life
Technologies, Inc. The transgene vector, p3300MCKCAT, was a gift from
Dr. Stephen Hauschka (University of Washington). Monoclonal anti-PP1c
antibodies that recognize all isoforms were generously provided by Dr.
Jackie Vandenheede (University of Leuven, Belgium) and anti-GS
antibodies by Dr. John C. Lawrence, Jr. (University of Virginia). DNA
sequencing was done at the Indiana University Biochemistry and
Biotechnology Facility (Indianapolis, IN) on an ABI PE-ABI 377XL laser
sequencer using fluorescent dideoxy terminators. Antiserum against
rabbit RGL was generated by immunizing rabbits with
recombinant His-RGL-(1-453) polypeptide. Reagents
for protein assays and electrophoresis were purchased from Bio-Rad.
Nitrocellulose membranes for Western blotting were from Millipore
(Bedford, MA), and chemiluminescence reagents were from Amersham
Pharmacia Biotech. All other chemicals and reagents were obtained from
either Sigma or Fisher.
Generation of RGLOE and KO Mice--
RGL KO mice were generated as described previously (38).
For generation of transgenic mice overexpressing RGL in
skeletal muscle, the full-length rabbit RGL cDNA (28)
was inserted at the BstEII site of the p3300MCKCAT
transgenic vector that contains the mouse muscle creatine kinase
promoter (MCK) (47). The HindIII and KpnI DNA
fragment that contains the promoter and the cDNA was microinjected
into the pronuclei of one-cell inbred C3Heb/FeJ embryos according to
the established protocols (48). The pups derived from the injected
embryos were screened for the presence of the transgene by polymerase
chain reaction as described previously (38). Oligonucleotides
5'-GGCAACGAGCTGAAAGCTCATCTGCTCTCAG-3' (ADPR279, sense primer in the
mouse MCK promoter) and 5'-CAAGTCAAACAGTGGAGATAAAACATATTC-3' (ADPR268,
antisense primer in the RGL cDNA were used. Three
positive animals were crossed with DBA/2J strains to establish
transgenic lineages. All mice were maintained in temperature- and
humidity-controlled conditions with a 12:12 h light/dark cycle and were
allowed access to food and water ad libitum. The transgenic
mice were generated at the Indiana University School of Medicine
Transgenic Facility, directed by Dr. Loren Field.
Western Blot Analyses--
Animals were sacrificed by cervical
dislocation, and skeletal muscles were excised, freeze-clamped in
liquid nitrogen, and stored at 80 °C until use. Frozen tissue
samples were homogenized in 10 volumes (w/v) of 50 mM
Tris/HCl, pH 7.5 (25 °C), 0.5 mM EDTA, 2 mM
EGTA, 100 mM NaF, 1% Triton X-100, 0.1 mM
N-p-tosyl-L-lysine chloromethyl ketone, 2 mM benzamidine, 0.5 mM phenylmethylsulfonyl fluoride, 50 mM -mercaptoethanol, and 10 µg/ml
leupeptin and homogenized using a Tissue Tearer model 285-370 (Biospec
Products Inc.) at 30,000 rpm for 20 s. The homogenates were then
centrifuged at 3,800 × g for 5 min. The resultant
supernatants were subjected to SDS-polyacrylamide gel electrophoresis.
Immunoblotting was performed as described previously (38), utilizing
appropriate antibodies. Antibody binding was detected by either
125I-labeled protein A or by enhanced chemiluminescence
procedures. Quantification was performed by densitometric scanning of
the films. Protein concentration was determined by the Bradford method (49) using bovine serum albumin as standard.
GS and Ph Assays--
GS and Ph activity were determined as
described previously (38) by measuring incorporation of
[14C]glucose from UDP-[14C]glucose into
glycogen (50) in the presence or absence of 7.2 mM glucose
6-phosphate and the incorporation of [14C]glucose into
glycogen from [14C]glucose 1-phosphate with or without 2 mM 5'-AMP (51), respectively. Activity ratios represent the
activity measured in the absence divided by that in the presence of the
allosteric effectors, G-6P or AMP.
Glycogen Determinations--
Glycogen content in skeletal muscle
was measured either by KOH hydrolysis of frozen muscle followed by
ethanol precipitation and amyloglucosidase digestion as described (38)
or by HCl hydrolysis of muscle homogenates followed by neutralization
as described (45). The resulting glucosyl residues were determined
spectrophotometrically using a hexokinase/glucose-6-phosphate
dehydrogenase-based assay (52).
Treadmill Exercise--
Mice were allowed first to become
adapted to treadmill (Quinton model 42) running by 5-10 min daily
training for 3 days. After removal of food for 5 h, 5-7-month-old
animals were then subjected to a "ramp" treadmill running protocol
in which the speed of the belt was held constant (0.6 mph), and the
incline was increased by 1° every 10 min until the mice were
exhausted. Maximal exercise tolerance was determined by the cumulative
amount of work (kJ) that the mice performed, calculated as body weight
(kg) × vertical distance covered (m) × 9.81. Blood samples
were collected from the tail vein for determination of glucose and
lactate concentrations before and after treadmill running. After
exercise mice were sacrificed by cervical dislocation, and the
gastrocnemius and tibialis anterior muscles were removed, snap-frozen
in liquid nitrogen, and subsequently processed for determination of
glycogen concentrations, glycogen synthase, and phosphorylase
activities. An equal number of mice were also sacrificed under basal
conditions, and blood and muscle samples were used for comparison to
the exercise group. Studies with RGL OE utilized animals
from line 3 and WT littermates that had been back-crossed 4 to 5 generations with DBA/2J.
In Situ Muscle Contraction--
After a 12-h overnight fast mice
were anesthetized with an intraperitoneal injection of pentobarbital
sodium (91 mg/kg). The sciatic nerves were bilaterally isolated, and
electrodes were placed around each and interfaced with a Grass model
S88 electrical stimulation unit (Quincy, MA). Hind limb muscles from
one leg were then stimulated to induce tetanic contractions for 15 min (1 train/s, 250 ms, 1 V, 0.2-ms duration), whereas the contralateral limb served as a non-stimulated control. Immediately following contractions, both extensor digitorum longus (EDL) muscles were removed
and used for measurement of [3H]2-deoxyglucose uptake, as
described previously (53), and glycogen content. Tibialis anterior and
gastrocnemius muscles were also removed, snap-frozen in liquid
nitrogen, and subsequently processed for determination of GS and Ph
activities, glycogen content, and Western blotting analyses.
Statistical Analyses--
All data are presented as means ± S.E. of the number of animals indicated in the figure legends.
Statistical significance was assessed by analysis of variance or
unpaired Student's t test.
 |
RESULTS |
Impaired Exercise Capacity in RGLKO Mice--
The
RGL knockout mice are characterized by low skeletal muscle
glycogen content (38). Since glycogen is a major source of energy
during exercise, a critical question was whether these animals would be
able to sustain exercise. Treadmill running showed that the knockout
mice had a 60% lower work capacity as compared with wild type
littermates (Table I). Consistent with
the previous report (38), basal muscle glycogen content in
RGL knockouts was significantly reduced. Since exercise has
been shown to decrease glycogen more readily in type II (fast twitch)
than in type I (slow twitch) muscle fibers (54), representatives of
both muscle types were analyzed. Although exhaustive treadmill exercise
depleted muscle glycogen by 30-50% in WT mice, the low basal glycogen
content in the KO mice was not further reduced by exercise
(Fig. 1). Similar results were obtained
with two different muscles, tibialis anterior (Fig. 1A), a
white muscle, and gastrocnemius (Fig. 1B), which is of mixed
red and white fiber types. No differences between WT and KO mice were
observed with respect to blood glucose or lactate concentration during
exercise (Table I).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of treadmill exercise on muscle
glycogen in WT and RGLKO mice. Glycogen content under
basal conditions (open bars) and following exhaustive
treadmill exercise (filled bars) of WT and RGL
KO mice was determined in tibialis anterior (A) and mixed
gastrocnemius (B) muscles by the HCl hydrolysis procedure as
described under "Experimental Procedures." Glycogen is expressed as
µmol glucose/g tissue. *, p < 0.05 versus
basal; #, p < 0.05 versus WT.
n = 4 per group. WT, wild type;
KO, knockout; B, basal; Ex, treadmill
exercise.
|
|
Altered Glycogen Metabolism during Exercise in RGLKO
Mice--
Other phenotypic characteristics of the RGL
knockout mice are reduced GS /+ G-6P and increased Ph /+ AMP
activity ratios (38). After treadmill exercise of WT mice, Ph activity
changed in a muscle-specific manner. In the tibialis anterior (Fig.
2A), treadmill running
increased the /+ AMP activity ratio, whereas in the mixed
gastrocnemius (Fig. 2B) the activity ratio was reduced. Exercise had no significant effect on Ph activity in either muscle of
the KO mice, possibly because of the close to maximal activation of the
enzyme under basal conditions.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of treadmill exercise on Ph and GS
activities in WT and RGLKO mice. Glycogen Ph
(A and B) and GS (C and D)
activity ratios were measured in tibialis anterior (A and
C) and in mixed gastrocnemius (B and
D) under basal conditions (open bars) and after
treadmill exercise (filled bars). Western blotting of GS
(E and F) was also performed on the same muscle
extracts using 10 µg of protein/lane. Note the increased
electrophoretic mobility of GS in the exercised WT muscles but not in
the KO muscles. *, p < 0.05 versus basal;
#, p < 0.05 versus WT. n = 4 per group. WT, wild type; KO, knockout;
B, basal and Ex, treadmill exercise.
|
|
GS activity state was also examined. As reported previously (38), the
basal activity in WT mice was significantly higher than in KO animals,
and treadmill running elicited an increase in GS /+ G-6P activity
ratio in both tibialis anterior (Fig. 2C) and gastrocnemius
(Fig. 2D) muscles of WT mice. In contrast, maximal treadmill
exercise did not increase GS activity in the muscles from KO mice.
Consistent with these findings, analysis of GS protein revealed an
increased electrophoretic mobility in samples from exercised WT but not
in KO mice, indicating that GS dephosphorylation was impaired in the
latter animals (Fig. 2, E and F). GS protein was
significantly reduced in both mixed gastrocnemius and tibialis anterior
muscles of KO mice and exhibited a slower mobility, consistent with
higher phosphorylation state and decreased activity ratio. These
findings provide compelling evidence that PP1G/RGL is
necessary for the dephosphorylation and activation of GS that occur in
skeletal muscle during exercise.
Effect of In Situ Muscle Contraction on GS Activity in WT and
RGLKO Mice--
It was possible that the lack of GS
activation and glycogen depletion observed in the KO mice following
exercise may have been due to the 60% lower work capacity. Therefore,
glycogen metabolism was also examined during electrically stimulated
in situ muscle contraction in order to standardize the
amount of muscular work performed by the different groups. In
situ contractions induced an increased GS activity in both the
tibialis anterior (Fig. 3C) and gastrocnemius (Fig. 3D) muscles of WT mice. Although
there was a tendency for decreased glycogen levels in the
gastrocnemius, the effect was not statistically significant (Fig.
3B). Similar to in vivo treadmill exercise,
in situ contractions did not reduce muscle glycogen content
(Fig. 3, A and B) or increase glycogen synthase
activity in muscles from KO mice (Fig. 3, C and
D), nor did it change Ph activity (Fig. 3F).
These data are consistent with the results of the in vivo
experiments, demonstrating that PP1G/RGL is essential for
the activation of GS that occurs in response to muscle contractions. To
monitor glucose uptake, we analyzed a small muscle suitable for this
analysis, the extensor digitorum longus (EDL). Following the
contraction protocol, [3H]2-deoxyglucose uptake rates
were equally increased over basal levels in both groups (Fig.
3E), indicating that RGL does not control
glucose transport either by contraction or by insulin (38). Glycogen
was determined in the same extracts (Fig. 3A), yielding
similar results to those with gastrocnemius (Fig. 3B).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of in situ electrical
stimulation on glycogen content, GS and Ph activity, and glucose uptake
in WT and RGLKO mice. Glycogen content was measured in
EDL (A) by the HCl hydrolysis procedure and in gastrocnemius
(B) by the KOH lysis method as described under
"Experimental Procedures" from unstimulated (open bars)
and electrically stimulated (filled bars) contralateral
muscles. GS activity ratio was measured in tibialis anterior
(C) and gastrocnemius (D); Ph activity ratio
was determined in gastrocnemius (F). Glucose uptake
(E) was determined in the EDL muscle. *, p < 0.001 versus basal; **, p < 0.001 versus basal; #, p < 0.03 versus
WT; ##, p < 0.0001 versus WT.
n = 7-14 per group. WT, wild type;
KO, knockout; B, basal and ES,
electrical stimulation.
|
|
Characterization of RGL-overexpressing
Mice--
Muscle-specific overexpression of RGL was driven
by the 3,300 to +7 promoter sequence of the mouse creatine kinase
gene (47) which directs expression mainly in skeletal muscle and to a
low level in heart. Of the three lines carrying the RGL
transgene, one did not overexpress the protein, whereas the other two
expressed up to 10-fold the level observed in rabbit, with a
concomitant ~6-fold increase of the endogenous PP1c (Fig.
4) in skeletal muscle. Since antibodies
raised against the rabbit RGL, the form expressed in the
transgenic mice, do not recognize the mouse protein, the level of
expression is expressed as a percentage of the level of normal rabbit
skeletal muscle. Western analysis utilizing antibodies to the mouse
protein indicated that the level of the endogenous RGL is
not changed (data not shown). Solubilization of RGL
required the presence of Triton X-100 in the homogenization buffer,
confirming that the protein is associated with membranes (28). The
increased endogenous PP1c is consistent with the decreased levels
observed in the RGL KO mice (38) and supports the
hypothesis that expression of the regulatory subunit stabilizes the
catalytic subunit. Neither Ph activity ratio nor total activity were
significantly affected by overexpression of RGL (data not
shown). Phosphatase activity measured with 32P-Ph
a as a substrate showed only 50% increase over basal. GS /+ G-6P activity ratio increased from 0.28 to 0.51 without changes in
the total activity or protein in muscle extracts (Fig.
5, A and C), and
the glycogen levels were enhanced by 3-4-fold (Fig. 5B).
Consistent with the increased GS activity ratio, an increased electrophoretic mobility of the protein was detected, indicative of
dephosphorylation (Fig. 5C). These observations provide
further evidence that PP1G/RGL is linked to glycogen
metabolism in skeletal muscle. Preliminary glucose uptake
determinations using isolated EDL muscle did not reveal significant
effects on glucose transport in transgenic mice as compared with wild
type littermates. To determine whether glucose disposal was altered,
glucose and insulin tolerance tests were performed. Fasted and fed
state blood glucose levels were in the normal range. Similarly, no
differences were detected between wild type and overexpressing mice in
glucose clearance following glucose load or insulin challenge (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
RGL and PP1c protein expression
in WT and in transgenic RGL OE mice. Hind limb
skeletal muscle extracts (40 µg of protein/lane) were subjected to
immunoblotting with anti-RGL (C, top) or
anti-PP1c (C, bottom) antibodies. A shows
quantitation of RGL by densitometric scanning of the
autoradiogram, expressed as percent of rabbit skeletal muscle
RGL. B shows quantitation of PP1c expressed as
percent of the mean of the WT. **, p < 0.01. n = 3-6 per group. WT, wild type;
RGL1, transgenic line 1;
RGL2, transgenic line 2;
RGL3, transgenic line 3; RSM,
rabbit skeletal muscle.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
GS activity ratio and expression and glycogen
content in WT and RGLOE mice. Glycogen synthase
activity ratio (A) and glycogen content (B) were
determined in skeletal muscle of WT and RGL-overexpressing
mice. C, upper part shows a Western blot of
representative extract samples (20 µg of protein/lane), and the
lower part shows quantitation of the autoradiogram. Note the
increased electrophoretic mobility of GS in the
RGL3-overexpressing mice. **, p < 0.01 versus WT. n = 5-12 per group.
GS<P, glycogen synthase with greater mobility indicative of
a lower phosphorylation state; GS>P, glycogen synthase with
lower mobility indicative of a higher phosphorylation state. Other
abbreviations are as in the legend to Fig. 4.
|
|
Increased Muscle Glycogen Content in the RGLOE Is Not
Associated with Enhanced Exercise Tolerance--
Despite the
differences in basal muscle glycogen content, RGL OE and WT
mice displayed a similar physical work capacity during the treadmill
running protocol (Table II). Blood
glucose concentrations were reduced below basal levels in both groups
following the exercise bout, but this occurred to a significantly
lesser extent in the OE mice (Table II). Blood lactate concentrations
were not altered by exercise in either group.
Exhaustive treadmill exercise reduced muscle glycogen content in both
tibialis anterior and gastrocnemius muscles of RGL OE (Fig.
6). GS and Ph activity ratios were not
significantly different in either the WT or OE mice following treadmill
exercise (data not shown).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
Muscle glycogen concentrations under basal
conditions and following treadmill exercise in WT and RGLOE
mice. Glycogen content was determined as in the legend to Fig. 1
under basal conditions (open bars) and after exhaustive
treadmill running (filled bars) of WT and RGL OE
mice. *, p = 0.003 versus basal; #,
p < 0.001 versus WT. n = 3-4 per group.
|
|
Glycogen Metabolism and Glucose Uptake by in Situ Contractions in
WT Mice and RGLOE--
In situ
contractions induced by electrical stimulation reduced muscle glycogen
content in the EDL muscle of OE mice by nearly 50% (Fig.
7A), but this effect did not
reach statistical significance in the mixed gastrocnemius muscle (Fig.
8B). The basal GS activity was
higher in the overexpressing muscles. Contractions increased the GS
activity ratio by approximately 2-fold in both tibialis anterior (Fig.
7B) and gastrocnemius (Fig. 8A) muscles of the WT
mice and in the gastrocnemius of the OE animals. Consistent with
activation of GS by electrical stimulation in gastrocnemius muscles of
both WT and overexpressing mice, the GS protein electrophoretic mobility was faster as shown in Fig. 8C. Contractions also
resulted in more than a 2-fold increase in the rates of
[3H]2-deoxyglucose uptake compared with basal rates in
EDL muscles from both WT and OE mice, but uptake rates were not
different between groups under either condition (Fig.
7C).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of in situ electrical
stimulation on glycogen content and GS and glucose uptake in WT and
RGLOE mice. Glycogen content (A) and GS
activity ratio (B) were measured in unstimulated (open
bars) and electrically stimulated (filled bars)
contralateral EDL and tibialis anterior muscles, respectively. Glucose
uptake was determined in EDL muscle, as described under "Experimental
Procedures." *, p < 0.01 versus basal; #,
p < 0.001 versus WT. n = 9-10 per group. Abbreviations are as in the legend to Fig. 1.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of in situ electrical
stimulation of gastrocnemius muscles on GS and Ph activity ratios and
on glycogen content in WT and RGLOE mice. GS
(A) activity ratio and glycogen content (B) were
measured in unstimulated (open bars) and electrically
stimulated (filled bars) contralateral gastrocnemius
muscles. C shows a Western blot of GS from representative
basal and electrically stimulated (ES) WT and
RGL-overexpressing muscles (12 µg of protein/lane). Note
the increased GS electrophoretic mobility following in situ
contraction, both in the WT and the OE animals. n = 11 (A) or 8 (B) per group. GS<P,
glycogen synthase with greater mobility indicative of a lower
phosphorylation state; GS>P, glycogen synthase with lower
mobility indicative of a higher phosphorylation state. **,
p < 0.001 versus basal; #,
p < 0.0001 versus WT.
RGL3, OE line 3.
|
|
 |
DISCUSSION |
The major finding of the current investigation is that the marked
increase in GS activity in skeletal muscle in response to both in
vivo exercise and in situ electrically induced
contraction is abolished in mice lacking the RGL,
regulatory/glycogen-targeting subunit of PP1G. In exercised WT mice,
the changes in GS activity state are accompanied by increased
electrophoretic mobility of the protein, diagnostic of
dephosphorylation. To date, the mechanism by which GS is activated
during muscle contractions has not been elucidated. It is well known
that the rate of glucose uptake is greatly increased in contracting
skeletal muscle, which is associated with an accumulation of G-6P
within the myoplasm (7). Increased G-6P concentration may provide a
mechanism for regulating GS during exercise via its allosteric effect
on activity and also by rendering GS more susceptible to
dephosphorylation by phosphatases (55). However, GS was not activated
in RGL KO mice despite the normal rates of basal and
post-contraction glucose uptake compared with WT mice, suggesting that
RGL mediates some other mechanism by which contraction
induces GS activation. Decreased phosphorylation of GS could be due to
decreased kinase activity, increased phosphatase activity, or both.
Changes in GS activity in skeletal muscle biopsies from exercising
humans have been associated with changes in the activity of a GS
phosphatase (46). However, these studies were correlative, and the
enzyme form was not identified. The results of the in vivo
and in situ experiments with RGL KO mice provide the first direct evidence that PP1G/RGL is a phosphatase
involved in the signaling cascade leading to activation of glycogen
synthase during exercise and additionally demonstrate that it is an
essential component of this control.
PP1G/RGL was originally proposed to mediate
insulin-stimulated glycogen synthesis in skeletal muscle via the MAP
kinase signaling pathway (32). Although subsequent studies using
epidermal growth factor (35), MAP kinase/extracellular signal-regulated
kinase kinase inhibitors (36), and RSK2 KO mice (37) argued against an
involvement of the MAP kinase signaling cascade, they did not exclude
the possibility that PP1G/RGL mediated the insulin
response. However, recent work (38) demonstrating normal activation of GS by insulin in RGL KO mice clearly showed that
PP1G/RGL is not required. Furthermore, although insulin may
increase phosphorylation of RGL at Ser48 and
Ser67 in cultured cell systems (56), it does not affect
phosphorylation at these sites in vivo either in rat (57) or
mouse (38) skeletal muscle. Activation of GS by PP1G/RGL
during muscle contraction appears to be a mechanism that is not shared
with the insulin signaling pathway, and insulin stimulation of GS
appears to involve a distinct phosphatase specific for GS (38). A large
body of evidence suggests that insulin and exercise control glucose
uptake by distinct mechanisms, mediated by IP-3K/Akt and AMPK,
respectively. Therefore, in a similar way, insulin and contraction may
stimulate GS through activation of different protein phosphatases.
Whether RGL is a downstream effector of AMPK is an
interesting question that is currently under investigation. However,
other pathways, such as elevation of intracellular
Ca2+concentration, cannot be excluded. It is unlikely that
RGL is controlled by the MAP kinase pathway, since the
MAP kinase kinase inhibitor PD98059 did not alter
contraction-induced increases in muscle glycogen synthase activity
(58).
Although our data indicate that PP1G/RGL is an obligatory
component of an exercise-activated signaling pathway that is not shared
by insulin, we cannot exclude the involvement of other mechanisms to
activate glycogen synthase during muscle contraction. Specific enzymes
in such pathways could represent points of convergence between insulin
and exercise signaling. For example, insulin activates a
PI-3K/Akt-dependent pathway that inhibits GSK-3 (39-41).
We have previously shown (45) that both GSK-3 and - isoforms are
inhibited in rat skeletal muscle during treadmill exercise. However, as for insulin signaling, GSK-3 alone cannot account for GS activation, since modulation of activity requires changes in the phosphorylation of
NH2-terminal phosphorylation sites that are not substrates for GSK-3 (3, 20, 21). Also, GSK-3 expression is not altered in the
RGL KO mice (38). Nevertheless, it is possible that
exercise-induced inhibition of GSK-3 plays an ancillary role in
activating GS, in a pathway shared with insulin. Further work is
required to identify what upstream effectors regulate
PP1G/RGL and GSK-3 during muscle contractions.
Both the RGL-overexpressing and KO mice exhibit differences
in basal muscle glycogen concentrations compared with their respective wild type littermates. The RGL-overexpressing animals have
significantly increased glycogen, whereas glycogen is severely depleted
in the KO mice. Analysis of GS and Ph activities in muscle extracts
indicates that these differences are due to alterations in the rates of both synthesis and degradation. Overexpression of related
phosphatase-targeting proteins, such as PTG, has been shown to promote
glycogen synthesis in hepatocytes in culture (30, 59) and in
vivo (60) and in cultured human muscle cells (31), presumably by
increasing phosphatase activity toward glycogen-bound substrates.
Although a role for PTG in insulin control of glycogen metabolism has
been proposed, our work indicates that PTG is not involved in
regulation by contraction. Most importantly, the present study
emphasizes the fact that the various forms of PP1G are not redundant
since neither the PTG nor the R6 forms of PP1G complemented the
inability of the RGL KO mice to activate GS in response to
contraction. Also, the fact that RGL overexpression did not
alter exercise performance or the ability to activate GS indicates that
gene dosage is not a critical factor. Various reports (62-65) have
argued that the intracellular glycogen content is inversely related to insulin- and exercise-induced stimulation of glucose transport and GS.
However, in the RGL OE and KO animals, the muscle glycogen content ranged from ~4-fold above normal to ~5-fold lower, without any observed differences in glucose uptake, whether basal,
contraction-induced, or insulin-induced (38). Therefore, our results
demonstrate that glycogen content by itself is not sufficient to
determine the activation potential of the two likely rate-determining
steps of its synthesis.
Muscle glycogen is a primary fuel source during muscle contractions and
may limit the duration of certain types of activities (66). Thus it was
perhaps not surprising that the RGL KO mice had a 60%
reduction in work capacity during maximal treadmill exercise. It is
interesting that the low basal muscle glycogen concentrations in the
knockouts, which were similar to post-exercise values in the WT
littermates, were not further reduced either by maximal treadmill
exercise or in situ contractions. Skeletal muscle appears to
contain different pools of glycogen that are subject to different
mechanisms of metabolic regulation, and thus a pool may exist that is
resistant to depletion by contractions (67). In humans, the rate of
glycogenolysis during exercise is significantly reduced in muscle with
a low pre-exercise glycogen concentration (68). Therefore, it seems
likely that the low basal glycogen content in the RGL KO
mice causes other fuel sources (e.g. blood glucose, amino
acids, and fatty acids) to become the primary fuel source during
exercise. The higher blood glucose levels observed in the
RGL-overexpressing mice after exercise lend some support to
this hypothesis. Additionally, branched chain amino acid oxidation has
been shown to be inversely related to post-exercise muscle glycogen
content in humans following prolonged cycle ergometry (69). If
RGL KO mice had an increased reliance on alternate fuel
substrates, such as amino acids and fatty acids, in an attempt to
preserve a "threshold" glycogen store during exercise, then a
reduced rate of ATP generation compared with anaerobic or aerobic
glycolysis may partly explain the reduced maximal exercise tolerance.
Although previous measurements of 24-h respiratory rates
(VO2/VCO2)
indicated that resting fuel substrate utilization in RGL KO
and WT mice was the same (38), there could be differences during
exercise, a possibility that merits further study. It has been reported
that depletion of RGL in L6 cells affects cell
differentiation (61), and abnormal muscle development could, in
principle, contribute to impaired exercise capacity. No comparable
phenomenon occurs in whole animals, however, since histological
analysis of various muscle types, including soleus, EDL, and
gastrocnemius, from RGL KO mice revealed no evidence for
morphological defects.2
In conclusion, although not required for GS stimulation by insulin
(38), RGL is an essential mediator of GS activation in response to skeletal muscle contractions. Therefore,
PP1G/RGL may be a component of a signaling cascade that is
unique to exercise. Work is in progress to determine the mechanism(s)
and the components of the signaling pathway that regulate
RGL and GSK-3 during exercise.
 |
ACKNOWLEDGEMENTS |
We acknowledge the guidance of Dr. Loren
Field, Director of the Transgenic Animal Facility at Indiana
University, in the generation of the RGL-overexpressing
mice. We thank Dr. Stephen Hauschka (University of Washington,
Seattle, WA) for providing the transgene vector,
p3300MCKCAT. We are particularly grateful to Dr. Peter J. Roach for
discussion of the work and for criticisms of the manuscript.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grant DK36569, by a research grant from the American Diabetes Association (to A. D. P. R.), and by National Institutes of Health Grants AR45670 and AR42238 (to L. J. G.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by National Research Service Award DK59769.
Present address: Dept. of Medical Genetics, Tohoku University
School of Medicine, 1-1 Seiryomachi Aoba-ku, Sendai 980-8574, Japan.

To whom correspondence should be addressed: Dept. of
Biochemistry and Molecular Biology, Indiana University School of
Medicine, 635 Barnhill Dr., Indianapolis, IN 46202-5122. Tel.:
317-274-1585; Fax: 317-274-4686; E-mail:
adepaoli@iupui.edu.
Published, JBC Papers in Press, August 24, 2001, DOI 10.1074/jbc.M105518200
2
D. Swartz and A. A. DePaoli-Roach,
unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
GS, glycogen
synthase;
Ph, glycogen phosphorylase;
PP1G, glycogen-associated type 1 serine/threonine protein phosphatase;
PP1c, catalytic subunit of PP1;
RGL(GM), regulatory subunit of
glycogen-associated PP1;
PTG, protein targeting to glycogen;
GSK-3, glycogen synthase kinase-3;
AMPK, AMP-activated protein kinase;
KO, knockout;
OE, overexpressors;
EDL, extensor digitorum
longus;
G-6P, glucose 6-phosphate;
MCK, muscle creatine
kinase;
WT, wild type;
MAP, mitogen-activated protein;
PI-3K, phosphatidylinositol 3-kinase.
 |
REFERENCES |
| 1.
|
Jue, T.,
Rothman, D. L.,
Tavitian, B. A.,
and Shulman, R. G.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1439-1442[Abstract/Free Full Text]
|
| 2.
|
Shulman, G. I.,
Rothman, D. L.,
Jue, T.,
Stein, P.,
DeFronzo, R. A.,
and Shulman, R. G.
(1990)
N. Engl. J. Med.
322,
223-228[Abstract]
|
| 3.
|
Lawrence, J. C., Jr.,
and Roach, P. J.
(1997)
Diabetes
46,
541-547[Abstract]
|
| 4.
|
Azpiazu, I.,
Manchester, J.,
Skurat, A. V.,
Roach, P. J.,
and Lawrence, J. C., Jr.
(2000)
Am. J. Physiol.
278,
E234-E243
|
| 5.
|
Price, T. B.,
Rothman, D. L.,
and Shulman, R. G.
(1999)
Proc. Nutr. Soc.
58,
851-859[Medline]
[Order article via Infotrieve]
|
| 6.
|
Price, T. B.,
Taylor, R.,
Mason, G. F.,
Rothman, D. L.,
Shulman, G. I.,
and Shulman, R. G.
(1994)
Med. Sci. Sports Exercise
26,
983-991[Medline]
[Order article via Infotrieve]
|
| 7.
|
Bloch, G.,
Chase, J. R.,
Meyer, D. B.,
Avison, M. J.,
Shulman, G. I.,
and Shulman, R. G.
(1994)
Am. J. Physiol.
266,
E85-E91[Abstract/Free Full Text]
|
| 8.
|
Ivy, J. L.,
and Kuo, C. H.
(1998)
Acta Physiol. Scand.
162,
295-304[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Lund, S.,
Holman, G. D.,
Schmitz, O.,
and Pedersen, O.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
5817-5821[Abstract/Free Full Text]
|
| 10.
|
Yeh, J. I.,
Gulve, E. A.,
Rameh, L.,
and Birnbaum, M. J.
(1995)
J. Biol. Chem.
270,
2107-2111[Abstract/Free Full Text]
|
| 11.
|
Lee, A. D.,
Hansen, P. A.,
and Holloszy, J. O.
(1995)
FEBS Lett.
361,
51-54[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Cushman, S. W.,
Goodyear, L. J.,
Pilch, P. F.,
Ralston, E.,
Galbo, H.,
Ploug, T.,
Kristiansen, S.,
and Klip, A.
(1998)
Adv. Exp. Med. Biol.
441,
63-71[Medline]
[Order article via Infotrieve]
|
| 13.
|
Winder, W. W.,
and Hardie, D. G.
(1999)
Am. J. Physiol.
277,
E1-E10
|
| 14.
|
Goodyear, L. J.
(2000)
Exercise Sport Sci. Rev.
28,
113-116[Medline]
[Order article via Infotrieve]
|
| 15.
|
Cohen, P.
(1986)
in
The Enzymes
(Boyer, P.
, and Krebs, E. G., eds), 3rd Ed
, pp. 461-497, Academic Press, Orlando
|
| 16.
|
Roach, P. J.
(1991)
J. Biol. Chem.
266,
14139-14142[Abstract/Free Full Text]
|
| 17.
|
Roach, P. J.,
Skurat, A. V.,
and Harris, R. A.
(2001)
in
Handbook of Physiology: The Endocrine Pancreas and Regulation of Metabolism
(Jefferson, L. S.
, and Cherrington, A. D., eds)
, pp. 609-647, Oxford University Press, New York
|
| 18.
|
Carling, D.,
and Hardie, D. G.
(1989)
Biochim. Biophys. Acta
1012,
81-86[Medline]
[Order article via Infotrieve]
|
| 19.
|
Lawrence, J. C., Jr.,
Hiken, J. F.,
DePaoli-Roach, A. A.,
and Roach, P. J.
(1983)
J. Biol. Chem.
258,
10710-10719[Abstract/Free Full Text]
|
| 20.
|
Skurat, A. V.,
Wang, Y.,
and Roach, P. J.
(1994)
J. Biol. Chem.
269,
25534-25542[Abstract/Free Full Text]
|
| 21.
|
Skurat, A. V.,
Dietrich, A. D.,
and Roach, P. J.
(2000)
Diabetes
49,
1096-1100[Abstract]
|
| 22.
|
Cohen, P.
(1987)
Biochem. Soc. Trans.
15,
999-1001[Medline]
[Order article via Infotrieve]
|
| 23.
|
Hubbard, M. J.,
and Cohen, P.
(1989)
Eur. J. Biochem.
180,
457-465[Medline]
[Order article via Infotrieve]
|
| 24.
|
Newgard, C. B.,
Brady, M. J.,
O'Doherty, R. M.,
and Saltiel, A. R.
(2000)
Diabetes
49,
1967-1977[Abstract/Free Full Text]
|
| 25.
|
Printen, J. A.,
Brady, M. J.,
and Saltiel, A. R.
(1997)
Science
275,
1475-1478[Abstract/Free Full Text]
|
| 26.
|
Armstrong, C. G.,
Browne, G. J.,
Cohen, P.,
and Cohen, P. T.
(1997)
FEBS Lett.
418,
210-214[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Stralfors, P.,
Hiraga, A.,
and Cohen, P.
(1985)
Eur. J. Biochem.
149,
295-303[Medline]
[Order article via Infotrieve]
|
| 28.
|
Tang, P. M.,
Bondor, J. A.,
Swiderek, K. M.,
and DePaoli-Roach, A. A.
(1991)
J. Biol. Chem.
266,
15782-15789[Abstract/Free Full Text]
|
| 29.
|
Fong, N. M.,
Jensen, T. C.,
Shah, A. S.,
Parekh, N. N.,
Saltiel, A. R.,
and Brady, M. J.
(2000)
J. Biol. Chem.
275,
35034-35039[Abstract/Free Full Text]
|
| 30.
|
Gasa, R.,
Jensen, P. B.,
Berman, H. K.,
Brady, M. J.,
DePaoli-Roach, A. A.,
and Newgard, C. B.
(2000)
J. Biol. Chem.
275,
26396-26403[Abstract/Free Full Text]
|
| 31.
|
Lerin, C.,
Montell, E.,
Berman, H. K.,
Newgard, C. B.,
and Gomez-Foix, A. M.
(2000)
J. Biol. Chem.
275,
39991-39995[Abstract/Free Full Text]
|
| 32.
|
Dent, P.,
Lavoinne, A.,
Nakielny, S.,
Caudwell, F. B.,
Watt, P.,
and Cohen, P.
(1990)
Nature
348,
302-308[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Nakielny, S.,
Campbell, D. G.,
and Cohen, P.
(1991)
Eur. J. Biochem.
199,
713-722[Medline]
[Order article via Infotrieve]
|
| 34.
|
Robinson, L. J.,
Razzack, Z. F.,
Lawrence, J. C., Jr.,
and James, D. E.
(1993)
J. Biol. Chem.
268,
26422-26427[Abstract/Free Full Text]
|
| 35.
|
Azpiazu, I.,
Saltiel, A. R.,
DePaoli-Roach, A. A.,
and Lawrence, J. C.
(1996)
J. Biol. Chem.
271,
5033-5039[Abstract/Free Full Text]
|
| 36.
|
Lazar, D. F.,
Wiese, R. J.,
Brady, M. J.,
Mastick, C. C.,
Waters, S. B.,
Yamauchi, K.,
Pessin, J. E.,
Cuatrecasas, P.,
and Saltiel, A. R.
(1995)
J. Biol. Chem.
270,
20801-20807[Abstract/Free Full Text]
|
| 37.
|
Dufresne, S. D.,
Bjorbaek, C.,
El-Haschimi, K.,
Zhao, Y.,
Aschenbach, W. G.,
Moller, D. E.,
and Goodyear, L. J.
(2001)
Mol. Cell. Biol.
21,
81-87[Abstract/Free Full Text]
|
| 38.
|
Suzuki, Y.,
Lanner, C.,
Kim, J.-H.,
Vilardo, P. G.,
Zhang, H.,
Jie Yang, J.,
Cooper, L. D.,
Steele, M.,
Kennedy, A.,
Bock, C.,
Scrimgeour, A.,
Lawrence, J. C. Jr., L.,
and DePaoli-Roach, A. A.
(2001)
Mol. Cell. Biol.
21,
2683-2694[Abstract/Free Full Text]
|
| 39.
|
Shepherd, P. R.,
Nave, B. T.,
and Siddle, K.
(1995)
Biochem. J.
305,
25-28
|
| 40.
|
Cross, D. A.,
Alessi, D. R.,
Cohen, P.,
Andjelkovich, M.,
and Hemmings, B. A.
(1995)
Nature
378,
785-789[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Welsh, G. I.,
and Proud, C. G.
(1993)
Biochem. J.
294,
625-629
|
| 42.
|
Cross, D. A.,
Watt, P. W.,
Shaw, M.,
van der Kaay, J.,
Downes, C. P.,
Holder, J. C.,
and Cohen, P.
(1997)
FEBS Lett.
406,
211-215[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Franch, J.,
Aslesen, R.,
and Jensen, J.
(1999)
Biochem. J.
344,
231-235
|
| 44.
|
O'Gorman, D. J.,
Del Aguila, L. F.,
Williamson, D. L.,
Krishnan, R. K.,
and Kirwan, J. P.
(2000)
J. Appl. Physiol.
89,
1412-1419[Abstract/Free Full Text]
|
| 45.
|
Markuns, J. F.,
Wojtaszewski, J. F.,
and Goodyear, L. J.
(1999)
J. Biol. Chem.
274,
24896-24900[Abstract/Free Full Text]
|
| 46.
|
Katz, A.,
and Raz, I.
(1995)
Pfluegers Arch. Eur. J. Physiol.
431,
259-265[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Johnson, J. E.,
Wold, B. J.,
and Hauschka, S. D.
(1989)
Mol. Cell. Biol.
9,
3393-3399[Abstract/Free Full Text]
|
| 48.
|
Hogan, B.,
Beddington, R.,
Constantini, F.,
and Lacy, E.
(1994)
Manipulating the Mouse Embryo: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 49.
|
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Thomas, J. A.,
Schlender, K. K.,
and Larner, J.
(1968)
Anal. Biochem.
25,
486-499[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Gilboe, D. P.,
Larson, K. L.,
and Nuttall, F. Q.
(1972)
Anal. Biochem.
47,
20-27[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Bergmeyer, H. U.,
Berndt, E.,
Schmidt, F.,
and Stork, H.
(1974)
in
Methods of Enzymatic Analysis
(Bergmeyer, H. U., ed), 2nd Ed., Vol. 3
, pp. 1196-1201, Academic Press, New York
|
| 53.
|
Hayashi, T.,
Hirshman, M. F.,
Fujii, N.,
Habinowski, S. A.,
Witters, L. A.,
and Goodyear, L. J.
(2000)
Diabetes
49,
527-531[Abstract]
|
| 54.
|
Ahlquist, L. E.,
Bassett, D. R.,
Sufit, R.,
Nagle, F. J.,
and Thomas, D. P.
(1992)
Eur. J. Appl. Physiol. Occup. Physiol.
65,
360-364[Medline]
[Order article via Infotrieve]
|
| 55.
|
Villar-Palasi, C.,
and Guinovart, J. J.
(1997)
FASEB J.
11,
544-558[Abstract]
|
| 56.
|
Liu, J.,
and Brautigan, D. L.
(2000)
J. Biol. Chem.
275,
15940-15947[Abstract/Free Full Text]
|
| 57.
|
Walker, K. S.,
Watt, P. W.,
and Cohen, P.
(2000)
FEBS Lett.
466,
121-124[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Hayashi, T.,
Hirshman, M. F.,
Dufresne, S. D.,
and Goodyear, L. J.
(1999)
Am. J. Physiol.
277,
C701-C707
|
| 59.
|
Berman, H. K.,
O'Doherty, R. M.,
Anderson, P.,
and Newgard, C. B.
(1998)
J. Biol. Chem.
273,
26421-26425[Abstract/Free Full Text]
|
| 60.
|
O'Doherty, R. M.,
Jensen, P. B.,
Anderson, P.,
Jones, J. G.,
Berman, H. K.,
Kearney, D.,
and Newgard, C. B.
(2000)
J. Clin. Invest.
105,
479-488[Medline]
[Order article via Infotrieve]
|
| 61.
|
Ragolia, L.,
Zuo, Q.,
and Begum, N.
(2000)
J. Biol. Chem.
275,
26102-26108[Abstract/Free Full Text]
|
| 62.
|
Laurent, D.,
Hundal, R. S.,
Dresner, A.,
Price, T. B.,
Vogel, S. M.,
Petersen, K. F.,
and Shulman, G. I.
(2000)
Am. J. Physiol.
278,
E663-E668
|
| 63.
|
Price, T. B.,
Laurent, D.,
Petersen, K. F.,
Rothman, D. L.,
and Shulman, G. I.
(2000)
J. Appl. Physiol.
88,
698-704[Abstract/Free Full Text]
|
| 64.
|
Kawanaka, K.,
Nolte, L. A.,
Han, D. H.,
Hansen, P. A.,
and Holloszy, J. O.
(2000)
Am. J. Physiol.
279,
E1311-E1318
|
| 65.
|
Derave, W.,
Lund, S.,
Holman, G. D.,
Wojtaszewski, J.,
Pedersen, O.,
and Richter, E. A.
(1999)
Am. J. Physiol.
277,
E1103-E1110
|
| 66.
|
Sherman, W. M.
(1995)
Am. J. Clin. Nutr.
62,
228-241
|
| 67.
|
Graham, T. E.,
Adamo, K. B.,
Shearer, J.,
Marchand, I.,
and Saltin, B.
(2001)
J. Appl. Physiol.
90,
873-879[Abstract/Free Full Text]
|
| 68.
|
Shearer, J.,
Marchand, I.,
Tarnopolsky, M. A.,
Dyck, D. J.,
and Graham, T. E.
(2001)
J. Appl. Physiol.
90,
880-888[Abstract/Free Full Text]
|
| 69.
|
Wagenmakers, A. J.,
Beckers, E. J.,
Brouns, F.,
Kuipers, H.,
Soeters, P. B.,
van der Vusse, G. J.,
and Saris, W. H.
(1991)
Am. J. Physiol.
260,
E883-E890[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Prats, J. W. Helge, P. Nordby, K. Qvortrup, T. Ploug, F. Dela, and J. F. P. Wojtaszewski
Dual Regulation of Muscle Glycogen Synthase during Exercise by Activation and Compartmentalization
J. Biol. Chem.,
June 5, 2009;
284(23):
15692 - 15700.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. S. Tagliabracci, J. M. Girard, D. Segvich, C. Meyer, J. Turnbull, X. Zhao, B. A. Minassian, A. A. DePaoli-Roach, and P. J. Roach
Abnormal Metabolism of Glycogen Phosphate as a Cause for Lafora Disease
J. Biol. Chem.,
December 5, 2008;
283(49):
33816 - 33825.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. El-Armouche, K. Wittkopper, F. Degenhardt, F. Weinberger, M. Didie, I. Melnychenko, M. Grimm, M. Peeck, W. H. Zimmermann, B. Unsold, et al.
Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy
Cardiovasc Res,
December 1, 2008;
80(3):
396 - 406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Fernandez, O. Hansson, P. Nevsten, C. Holm, and C. Klint
Hormone-sensitive lipase is necessary for normal mobilization of lipids during submaximal exercise
Am J Physiol Endocrinol Metab,
July 1, 2008;
295(1):
E179 - E186.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-C. Lai, J. T. Stuenaes, C.-H. Kuo, and J. Jensen
Glycogen content and contraction regulate glycogen synthase phosphorylation and affinity for UDP-glucose in rat skeletal muscles
Am J Physiol Endocrinol Metab,
December 1, 2007;
293(6):
E1622 - E1629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Pratt, R. J. Geor, L. L. Spriet, and L. J. McCutcheon
Time course of insulin sensitivity and skeletal muscle glycogen synthase activity after a single bout of exercise in horses
J Appl Physiol,
September 1, 2007;
103(3):
1063 - 1069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Gibbons, L. Kozubowski, K. Tatchell, and S. Shenolikar
Expression of Human Protein Phosphatase-1 in Saccharomyces cerevisiae Highlights the Role of Phosphatase Isoforms in Regulating Eukaryotic Functions
J. Biol. Chem.,
July 27, 2007;
282(30):
21838 - 21847.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Rose, T. J. Alsted, J. B. Kobbero, and E. A. Richter
Regulation and function of Ca2+-calmodulin-dependent protein kinase II of fast-twitch rat skeletal muscle
J. Physiol.,
May 1, 2007;
580(3):
993 - 1005.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. G. Aschenbach, R. C. Ho, K. Sakamoto, N. Fujii, Y. Li, Y.-B. Kim, M. F. Hirshman, and L. J. Goodyear
Regulation of Dishevelled and beta-catenin in rat skeletal muscle: an alternative exercise-induced GSK-3beta signaling pathway
Am J Physiol Endocrinol Metab,
July 1, 2006;
291(1):
E152 - E158.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Baker, P. L. Greenhaff, A. MacInnes, and J. A. Timmons
The Experimental Type 2 Diabetes Therapy Glycogen Phosphorylase Inhibition Can Impair Aerobic Muscle Function During Prolonged Contraction
Diabetes,
June 1, 2006;
55(6):
1855 - 1861.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Hardie and K. Sakamoto
AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle
Physiology,
February 1, 2006;
21(1):
48 - 60.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Greenberg, A. M. Danos, and M. J. Brady
Central Role for Protein Targeting to Glycogen in the Maintenance of Cellular Glycogen Stores in 3T3-L1 Adipocytes
Mol. Cell. Biol.,
January 1, 2006;
26(1):
334 - 342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-B. Kim, O. D. Peroni, W. G. Aschenbach, Y. Minokoshi, K. Kotani, A. Zisman, C. R. Kahn, L. J. Goodyear, and B. B. Kahn
Muscle-Specific Deletion of the Glut4 Glucose Transporter Alters Multiple Regulatory Steps in Glycogen Metabolism
Mol. Cell. Biol.,
November 1, 2005;
25(21):
9713 - 9723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Kirchhefer, H. A. Baba, P. Boknik, K. M. Breeden, N. Mavila, N. Bruchert, I. Justus, M. Matus, W. Schmitz, A. A. DePaoli-Roach, et al.
Enhanced cardiac function in mice overexpressing protein phosphatase Inhibitor-2
Cardiovasc Res,
October 1, 2005;
68(1):
98 - 108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Ruzzin and J. Jensen
Contraction activates glucose uptake and glycogen synthase normally in muscles from dexamethasone-treated rats
Am J Physiol Endocrinol Metab,
August 1, 2005;
289(2):
E241 - E250.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. A. Pederson, C. R. Cope, J. M. Schroeder, M. W. Smith, J. M. Irimia, B. L. Thurberg, A. A. DePaoli-Roach, and P. J. Roach
Exercise Capacity of Mice Genetically Lacking Muscle Glycogen Synthase: IN MICE, MUSCLE GLYCOGEN IS NOT ESSENTIAL FOR EXERCISE
J. Biol. Chem.,
April 29, 2005;
280(17):
17260 - 17265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sacchetto, E. Bovo, A. Donella-Deana, and E. Damiani
Glycogen- and PP1c-targeting Subunit GM Is Phosphorylated at Ser48 by Sarcoplasmic Reticulum-bound Ca2+-Calmodulin Protein Kinase in Rabbit Fast Twitch Skeletal Muscle
J. Biol. Chem.,
February 25, 2005;
280(8):
7147 - 7155.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. B. Jorgensen, J. N. Nielsen, J. B. Birk, G. S. Olsen, B. Viollet, F. Andreelli, P. Schjerling, S. Vaulont, D. G. Hardie, B. F. Hansen, et al.
The {alpha}2-5'AMP-Activated Protein Kinase Is a Site 2 Glycogen Synthase Kinase in Skeletal Muscle and Is Responsive to Glucose Loading
Diabetes,
December 1, 2004;
53(12):
3074 - 3081.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Fujii, M. D. Boppart, S. D. Dufresne, P. F. Crowley, A. C. Jozsi, K. Sakamoto, H. Yu, W. G. Aschenbach, S. Kim, H. Miyazaki, et al.
Overexpression or ablation of JNK in skeletal muscle has no effect on glycogen synthase activity
Am J Physiol Cell Physiol,
July 1, 2004;
287(1):
C200 - C208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Y. Alcoser, M. Hara, G. I. Bell, and D. A. Ehrmann
Association of the (AU)AT-Rich Element Polymorphism in PPP1R3 with Hormonal and Metabolic Features of Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab.,
June 1, 2004;
89(6):
2973 - 2976.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. C. Carmody, P. A. Bauman, M. A. Bass, N. Mavila, A. A. DePaoli-Roach, and R. J. Colbran
A Protein Phosphatase-1{gamma}1 Isoform Selectivity Determinant in Dendritic Spine-associated Neurabin
J. Biol. Chem.,
May 21, 2004;
279(21):
21714 - 21723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Yu, N. Fujii, M. F. Hirshman, J. M. Pomerleau, and L. J. Goodyear
Cloning and characterization of mouse 5'-AMP-activated protein kinase {gamma}3 subunit
Am J Physiol Cell Physiol,
February 1, 2004;
286(2):
C283 - C292.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
H. CEULEMANS and M. BOLLEN
Functional Diversity of Protein Phosphatase-1, a Cellular Economizer and Reset Button
Physiol Rev,
January 1, 2004;
84(1):
1 - 39.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Y. Christ-Roberts, T. Pratipanawatr, W. Pratipanawatr, R. Berria, R. Belfort, and L. J. Mandarino
Increased insulin receptor signaling and glycogen synthase activity contribute to the synergistic effect of exercise on insulin action
J Appl Physiol,
December 1, 2003;
95(6):
2519 - 2529.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. Sakamoto, W. G. Aschenbach, M. F. Hirshman, and L. J. Goodyear
Akt signaling in skeletal muscle: regulation by exercise and passive stretch
Am J Physiol Endocrinol Metab,
November 1, 2003;
285(5):
E1081 - E1088.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Lerin, E. Montell, T. Nolasco, C. Clark, M. J. Brady, C. B. Newgard, and A. M. Gomez-Foix
Regulation and Function of the Muscle Glycogen-Targeting Subunit of Protein Phosphatase 1 (GM) in Human Muscle Cells Depends on the COOH-Terminal Region and Glycogen Content
Diabetes,
September 1, 2003;
52(9):
2221 - 2226.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Sakamoto and L. J. Goodyear
Exercise Effects on Muscle Insulin Signaling and Action: Invited Review: Intracellular signaling in contracting skeletal muscle
J Appl Physiol,
July 1, 2002;
93(1):
369 - 383.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. P. Wojtaszewski, J. N. Nielsen, and E. A. Richter
Exercise Effects on Muscle Insulin Signaling and Action: Invited Review: Effect of acute exercise on insulin signaling and action in humans
J Appl Physiol,
July 1, 2002;
93(1):
384 - 392.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N Nielsen, J. F P Wojtaszewski, R. G Haller, D G. Hardie, B. E Kemp, E. A Richter, and J. Vissing
Role of 5'AMP-activated protein kinase in glycogen synthase activity and glucose utilization: insights from patients with McArdle's disease
J. Physiol.,
June 15, 2002;
541(3):
979 - 989.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Sakamoto, M. F. Hirshman, W. G. Aschenbach, and L. J. Goodyear
Contraction Regulation of Akt in Rat Skeletal Muscle
J. Biol. Chem.,
March 29, 2002;
277(14):
11910 - 11917.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|